R1 RCM forms special committee to evaluate strategic alternatives

R1 RCM announced the formation of a special committee comprised solely of independent directors to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C. with the Securities and Exchange Commission on February 26, 2024. The Company issued the following statement: “R1 welcomes open, constructive communications with all stockholders and encourages input that advances our shared goal of enhancing stockholder value. Consistent with its fiduciary duties, and in consultation with its independent advisors, the Special Committee will carefully review the communications from New Mountain Capital and evaluate strategic alternatives to determine the course of action that it believes is in the best interests of R1 and its stockholders. R1 remains focused on providing clients with world-class revenue cycle solutions to help providers improve their financial performance and deliver an exceptional patient experience. No assurances can be given regarding the outcome or timing of the Special Committee’s review process. R1 does not intend to make any further public comment regarding the review unless and until it has approved a course of action for which further disclosure is appropriate.”